.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

OPTISON Drug Profile

« Back to Dashboard
Optison is a drug marketed by Ge Healthcare and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has thirty-nine patent family members in twenty-seven countries.

The generic ingredient in OPTISON is albumin human. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.

Summary for Tradename: OPTISON

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: OPTISON

Clinical Trials for: OPTISON

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997RXYes6,723,303Apr 20, 2021Y
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997RXYesAug 17, 2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OPTISON

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 19975,529,766<disabled>
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 19975,573,751<disabled>
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 19975,558,094<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OPTISON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,393,524 Methods for selecting and using gases as ultrasound contrast media<disabled in preview>
5,666,526 Method and system for supporting scrollable, updatable database queries<disabled in preview>
6,156,292 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OPTISON

Country Document Number Estimated Expiration
Australia2550392<disabled in preview>
Hungary9400786<disabled in preview>
Canada2119129<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OPTISON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00673Netherlands<disabled>PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
C0050France<disabled>PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/428/001 DU 20080111; REGISTRATION NO/DATE AT EEC: EU/1/07/428/001 DU 20080111
0673Netherlands<disabled>PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc